Virtus ETF Advisers’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Virtus ETF Advisers’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-68	Closed	-$85K	–	467
2022 Q1	$85K	Sell	68 -4	-6%	-$5.44K	0.04%	329
2021 Q4	$183K	Buy	72 +50	+227%	+$305K	0.07%	241
2021 Q3	$410K	Sell	22 -2	-8%	-$31.8K	0.18%	168
2021 Q2	$249K	Sell	24 -26	-52%	-$218K	0.1%	213
2021 Q1	$359K	Buy	50 +1	+2%	+$7.2K	0.15%	205
2020 Q4	$272K	Buy	49 +15	+44%	+$133K	0.11%	269
2020 Q3	$342K	Sell	34 -5	-13%	-$45.5K	0.18%	192
2020 Q2	$360K	Sell	39 -7	-15%	-$64.1K	0.17%	252
2020 Q1	$420K	Sell	46 -7	-13%	-$69.1K	0.17%	192
2019 Q4	$592K	Buy	+53	New	+$320K	0.1%	191

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Virtus ETF Advisers's IRLA Position: Q2 2022 in Review

Virtus ETF Advisers sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 68 shares — an estimated $85K sold.

Virtus ETF Advisers first reported a position in IRLA in Q4 2019 and held it in 10 quarters. The position peaked at $592K in Q4 2019. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Virtus ETF Advisers reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 68 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $85K.
Virtus ETF Advisers first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Virtus ETF Advisers's IRulya Therapeutics Inc. Common Stock position peaked at $592K in Q4 2019.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.